Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan;
Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan.
Anticancer Res. 2024 Aug;44(8):3525-3531. doi: 10.21873/anticanres.17173.
BACKGROUND/AIM: The outcomes of lung cancer treatment have improved over time. However, in contrast to other treatments, the clinical outcomes of salvage surgery are seldom reported because the follow-up periods after salvage surgery are short.
We conducted a comprehensive study involving consecutive patients who underwent salvage surgery at two different institutions. Our analysis encompassed the exploration of clinicopathological features, perioperative variables, and surgical outcomes. Additionally, we employed propensity score matching to compare the long-term survival of patients with non-small cell lung cancer (NSCLC) who underwent salvage surgery with those who received induction chemoradiotherapy prior to surgery.
Twenty-five patients underwent salvage procedures, while 113 patients received induction chemotherapy followed by surgery during the same study period. When assessing the overall survival (OS) from the registration date to the initial treatment date, the five-year OS rates were 73.8% in the induction group and 70.5% in the salvage surgery group (p=0.674). No significant differences were identified between the two groups in a cohort of 48 patients with NSCLC who were matched using propensity scores.
In patients who underwent salvage surgery, reasonable long-term survival was achieved with outcomes comparable to those of induction chemotherapy followed by surgical resection.
背景/目的:肺癌治疗的疗效随着时间的推移而提高。然而,与其他治疗方法相比,挽救性手术的临床疗效很少被报道,因为挽救性手术后的随访时间较短。
我们对在两个不同机构接受挽救性手术的连续患者进行了一项全面研究。我们分析了临床病理特征、围手术期变量和手术结果。此外,我们还采用倾向评分匹配比较了接受挽救性手术的非小细胞肺癌(NSCLC)患者与术前接受诱导化疗和放疗的患者的长期生存情况。
25 例患者接受了挽救性手术,113 例患者在同一研究期间接受了诱导化疗后手术。从登记日期到初始治疗日期评估总生存率(OS)时,诱导组的 5 年 OS 率为 73.8%,挽救性手术组为 70.5%(p=0.674)。在使用倾向评分匹配的 48 例 NSCLC 患者队列中,两组之间没有发现显著差异。
在接受挽救性手术的患者中,实现了合理的长期生存,其结果与诱导化疗后手术切除相当。